Mitchell Levinson has been appointed to Pulse Biosciences board of directors. In connection with his appointment to the board, Mr. Levinson will also serve as a member of the audit committee.
“Mitch is an ideal addition to our Board because of his considerable expertise in developing and bringing revolutionary new products to the aesthetic dermatology market,” said Darrin Uecker, President and Chief Executive Officer. “His experience will be a significant asset as we are working to introduce our CellFX System into this market later in 2019.”
Levinson, 58, has more than 25 years of experience bringing novel medical technologies to the market, including over a decade in the aesthetics procedure market. Levinson previously founded and served as CEO and CSO of Zeltiq Aesthetics from 2005 to 2010 overseeing the development and facilitating the early commercial launch of its flagship CoolSculpting procedure. Prior to Zeltiq, he served as the initial Vice President of Research and Development for Thermage from 2000 to 2005 where he built the R&D organization and led the development of Thermage’s novel skin tightening technology. Mr. Levinson is currently a board member and Chief Technology Officer of Cerebrotech, an innovative neurotechnology device company focused on the development of portable neurotechnology solutions, that he founded during 2010.
Levinson previously served on the Pulse Biosciences board from January 2015 to November 2017, during which time the Company conducted its initial public offering and commenced clinical studies. He also currently serves on the board of directors of ConnectWell, a leading-edge provider of digital health and wellness content.
Mr. Levinson earned his BS in Mechanical Engineering from University of California at San Diego, holds an M.S. in Computer Systems from the University of Phoenix, and is inventor on 45 issued U.S. patents.